About this trial
This study aims to assess the association of Anti-Müllerian hormone (AMH) with polycystic ovarian syndrome, premature ovarian insufficiency and fertility. The main objectives include the following:
1. To study the level of serum AMH in women with PCOS and to evaluate the utility of serum AMH in the diagnosis of PCOS. 2. To evaluate the level of serum AMH in women with POI and to evaluate the utility of serum AMH in the management of POI. 3. To evaluate the associations of basal AMH level with FSH level and AFC respectively for women undergoing ART treatment. 4. To determine the optimal regimen of gonadotropin for ovarian stimulation for women undergoing ART treatment. 5. To evaluate the predictive value of serum AMH in reproductive outcomes including oocyte quality, embryo quality, pregnancy loss, clinical pregnancy and live birth rate in women undergoing ART treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI
Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment
Disqualifiers
Women with age <10 or ≥45
Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion
Trial population
The following clients will be included in our study population. * Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI * Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Serum anti-Müllerian hormone (AMH) (pmol/L)
To evaluate the serum AMH level of women who undergo investigation for polycystic ovarian syndrome (PCOS), premature ovarian insufficiency (POI) or subfertility
Secondary outcomes
Type of gonadotropin used for ovarian stimulation
To assess the type of gonadotropin used for ovarian stimulation for women undergoing ART treatment
Total gonadotropin dose used for ovarian stimulation
To assess the total gonadotropin dose used for ovarian stimulation for women undergoing ART treatment
Number of oocytes retrieved
To evaluate the number of oocytes retrieved during oocyte retrieval for women undergoing ART treatment
Serum follicle stimulation hormone (FSH) (IU/L)
To evaluate the serum FSH level of women who undergo ART treatment
Sponsors and contacts
Click on the lead sponsor to view all of their trials.